Research Insight
FDA approves Amgen’s BLA for high cholesterol treatment evolocumab
Amgen has received approval for review from US Food and Drug Administration (FDA) for its evolocumab to treat high cholesterol. The FDA accepted Biologics License Application (BLA) for evolocumab, an investigational fully human monoclonal antibody that...
Research Insight
Takeda and GE Healthcare partner to develop therapeutic drugs for liver diseases
Japan-based Takeda Pharmaceutical has signed an alliance agreement with GE Healthcare for research and development of hepatic fibrosis. Hepatic fibrosis is an important factor in the diagnosis and treatment of liver diseases. Terms of the agreement...
Research Insight
ex scientia Ltd. Partners with Sunovion Pharmaceuticals Inc. to Research New Medicines for Psychiatric Disorders ex scientia Ltd.
exscientia Ltd. the polypharmacology driven drug discovery company announced today that they have signed an agreement with Sunovion Pharmaceuticals Inc. to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders. ...
Research Insight
AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approvalAstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approval
British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes. Xigduo XR is a combination of two...
Research Insight
Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B disease
US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults. As part of the breakthrough therapy designation...
Research Insight
Hikma to market Eisai’s epilepsy treatment Fycompa in Middle East
UK-based Hikma Pharmaceuticals has partnered with Eisai to distribute first-class epilepsy treatment Fycompa (perampanel) in the Middle East. Eisai has developed Fycompa to treat partial onset seizures, with or without secondarily generalised seizures,...
Research Insight
Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infection
Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype 1 infection in adults. Obtained approval...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read